

**ANCOVA of Change from Baseline in  
Fasting Glucose (mmol/L) at Week 24 (LOCF)  
Efficacy Analysis Population**

<b>Treatment Group</b>	<b>Baseline</b>		<b>Week 24 (LOCF)</b>		<b>Change from Baseline</b>		<b>LS Mean (95% CI)<sup>a</sup></b>
	<b>N</b>	<b>Mean (SD)</b>	<b>N</b>	<b>Mean (SD)</b>	<b>N</b>	<b>Mean (SD)</b>	
Placebo	79	5.7 (2.23)	79	5.6 (1.65)	79	-0.0 (2.32)	0.07 (-0.26, 0.41)
Xanomeline Low Dose	79	5.4 (0.95)	79	5.4 (1.06)	79	-0.1 (1.02)	-0.11 (-0.44, 0.23)
Xanomeline High Dose	74	5.4 (1.37)	74	5.8 (2.21)	74	0.4 (1.65)	0.39 (0.04, 0.74)
<b>Pairwise Comparison</b>	<b>Difference in LS Mean (95% CI)<sup>a</sup></b>					<b>p-Value<sup>b</sup></b>	
Xanomeline Low Dose vs. Placebo	-0.18 (-0.65, 0.30)						0.4670
Xanomeline High Dose vs. Placebo	0.32 (-0.17, 0.80)						0.2004

<sup>a</sup>LS means and differences in LS means are based on an ANCOVA model with treatment and baseline glucose as covariates.

<sup>b</sup>p-values are from the ANCOVA model testing treatment effects

LOCF (Last Observation Carried Forward) approach is used for missing Week 24 values.

ANCOVA = Analysis of Covariance; CI = Confidence Interval; LS = Least Squares; SD = Standard Deviation

Source: ADLBC Analysis Dataset

Analysis conducted: 15NOV2025

Statistical software: Python (statsmodels)